Skip to main
UNCY

Unicycive Therapeutics (UNCY) Stock Forecast & Price Target

Unicycive Therapeutics (UNCY) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Unicycive Therapeutics is expected to see positive updates in their quarterly financial results, with modest increases in SG&A balanced by decreases in R&D. The company has also made progress in obtaining FDA approval for their key product OLC, despite last year's CRL. Additionally, they have a potential launch in 3Q 2026 and are actively working on securing reimbursement for OLC. These factors, along with a positive regulatory outlook and a strong focus on addressing unmet medical needs, contribute to our positive outlook on the stock.

Bears say

Unicycive Therapeutics is facing several challenges that could negatively impact its sales potential and valuation. These include potential delays or setbacks in bringing OLC to market, difficulty obtaining reimbursement for the product, and challenges with commercial execution by the Unicycive team. In addition, the company has a significant amount of debt and may need to raise additional capital, which could dilute current shareholders. As a result, the company is not expected to be profitable until 2027, putting it at a disadvantage compared to its competitors.

Unicycive Therapeutics (UNCY) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Unicycive Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Unicycive Therapeutics (UNCY) Forecast

Analysts have given Unicycive Therapeutics (UNCY) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Unicycive Therapeutics (UNCY) has a Strong Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $25.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $25.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Unicycive Therapeutics (UNCY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.